On December 3, 2020 The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) reported five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib (Press release, NCCN, DEC 3, 2020, View Source [SID1234572151]). Abemaciclib is a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The proposals were reviewed and awarded by a scientific steering committee made up of experts from NCCN Member Institutions, and the NCCN ORP is handling project oversight. Research funding is being provided by a grant from Eli Lilly and Company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The selected projects are:
A Prospective, Multi-Center, Biomarker Driven Trial to Evaluate the Efficacy and Safety of Abemaciclib Monotherapy Beyond First Line CDK4/6 Inhibition in ER + Breast Cancer (AMBER)
Aditya Bardia, MD, MPH, Massachusetts General Hospital Cancer Center and Seth Wander, MD, PhD, Harvard Medical School
Refractory Hormone Receptor Positive Breast Cancer: A Role for Estrogen Receptor β
Mathew Cherian, MBBS, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
A Preclinical Study of Abemaciclib in Combination with Merestinib Against Breast Cancer Brain Metastasis *
Inan Olmez, MD, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Blockade of ER Positive Breast Cancers
Mateusz Opyrchal, MD, PhD, Washington University in St. Louis
PET Imaging of Cell Cycle Arrest for Predicting Response to Abemaciclib Alone or in Combination with Endocrine Therapy *
Chenbo Zeng, PhD, Abramson Cancer Center at the University of Pennsylvania
"Congratulations to all of these accomplished grantees," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "We are eager to learn more about which patients develop resistance to CDK 4 & 6 inhibitors, the potential underlying mechanisms, and ways in which such resistance can be overcome, in order to improve the application of this potentially life-prolonging therapy. This research is one of the many ways we work to improve longevity and quality-of-life for people with metastatic breast cancer."
"I have had a frontline view of how metastatic breast cancer can be unpredictable and complex," said Maura Dickler, MD, Vice President, Late Phase Development, Lilly Oncology. "Every day the lives of an estimated 115 women and men in the United States are lost as a result of this disease. Lilly is honored to support this research because it is critical in furthering our efforts to improve treatment options for people living with metastatic breast cancer."
The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.
* The preclinical studies by Drs. Olmez and Zeng have already begun. The remainder are expected to commence in mid-2021.